Pimodivir Plus Oseltamivir Does Not Demonstrate Clinical Benefit In Terms Of Efficacy Among Hospitalized Patients With Influenza A, Study Finds

Infectious Disease Advisor (10/1, Basilio) reports, “Among hospitalized patients infected with influenza A, treatment with pimodivir plus oseltamivir vs oseltamivir alone did not demonstrate measurable clinical benefit in terms of efficacy; however, in outpatients at high risk for influenza-related complications, pimodivir plus oseltamivir vs oseltamivir alone demonstrated clinical benefit in terms of shorter time to resolution of [influenza] symptoms, according to study results.” Researchers found that “a high proportion of patients in the pimodivir plus standard of care (45.1%) vs placebo plus standard of care (37.3%) group experienced treatment-emergent” adverse events “in the outpatient study.” The findings were published in The Journal of Infectious Diseases.